![]() ![]() Unlike other schedule I substances such as heroin, and schedule II compounds, including cocaine and fentanyl, psilocybin exhibits a low risk of toxicity and a very low potential for dependence or addiction 6. The evidence in support of rescheduling is strong, particularly for psilocybin, which is derived from fungi 5. The schedule I status of most psychedelics imposes a ceiling on many policy recommendations. Clinical trials have now been conducted at leading universities, and a growing body of evidence supports the use of psychedelics, such as psilocybin and MDMA, in the treatment of depression 2, post-traumatic stress disorder 3 and anxiety toward the end of life 4. ![]() In the late 1990s, the US Drug Enforcement Administration (DEA) permitted some researchers to study limited amounts of psychedelics, which allowed research to resume. However, in the 1970s they were categorized as schedule I controlled substances, which are said to have “no currently accepted medical use and a high potential for abuse” this blocked mainstream research on these compounds for decades. By the middle of the 20th century, clinicians used psychedelics as adjuncts to psychotherapy, reporting a variety of benefits. Others were first synthesized in the early 20th century. Some psychedelics have been used by Indigenous communities for hundreds or thousands of years. ![]() Psychedelics are a class of natural and synthetic compounds that includes psilocybin, MDMA (3,4-methylenedioxymethamphetamine), ibogaine and DMT (dimethyltryptamine). ![]()
0 Comments
Leave a Reply. |